Liprolog

Insulin lispro, the active ingredient in Liprolog, is a rapid‑acting insulin analog presented as a solution for injection for intravenous, subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients. GNH USA supplies Liprolog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liprolog is a rapid‑acting insulin analog used to manage blood glucose in diabetes mellitus.

Type 1 diabetes mellitus: provides rapid insulin coverage to control post‑prandial glucose spikes. Type 2 diabetes mellitus: used as part of intensive insulin therapy to improve glycemic control, especially around meals.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilization. - Lipodystrophy: localized changes in fat tissue with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycemia: can cause seizures, loss of consciousness, or require emergency assistance. - Anaphylactic reaction: rare systemic allergic response requiring immediate medical care. - Hypokalemia: low potassium levels, potentially leading to cardiac arrhythmias.

When using Liprolog, consider the following precautions: - Dose titration: adjust based on frequent blood glucose monitoring and clinical response. - Hypoglycemia risk: educate patients on recognizing symptoms and appropriate treatment. - Renal impairment: monitor closely as insulin clearance may be reduced. - Pregnancy: use only if benefits outweigh potential risks to the fetus. - Drug interactions: review all concomitant medications for possible glycemic effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liprolog may interact with several drug classes.

Major Interactions (Avoid): - Sulfonylureas: combined use can markedly increase risk of severe hypoglycemia. - Beta‑blockers: may mask typical hypoglycemia warning signs, complicating detection.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: can potentiate insulin’s glucose‑lowering effect, requiring dose review. - Thiazide diuretics: may raise blood glucose, potentially necessitating insulin dose adjustment. - Alcohol: can cause delayed hypoglycemia, especially when consumed with meals.